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Abstract : Heart failure （HF） is a common disease in elderly patients, particularly 
in those presenting as readmission for worsening HF.  While recent studies have 
revealed mortality-associated factors in this population, little is known about prog-
nostic factors associated with worsening HF.  To investigate this clinical evidence 
gap in patients aged over 75 years, we retrospectively investigated 165 patients 
hospitalized for HF at Showa University Hospital, of whom 65 （39.4％） were read-
mitted for worsening HF.  We extracted the candidate variables based on univariate 
analysis, and then elucidated the independent prognostic factors by multivariate 
analysis.  Compared with non-readmitted patients, readmitted patients with worsen-
ing HF had lower left ventricular ejection fraction （LVEF） （39％ vs. 50％, P＝
0.002） and body mass index （BMI） （19.9 kg/m2 vs. 21.4 kg/m2, P＝0.007）, higher 
levels of B-type natriuretic peptide （BNP） （478 pg/ml vs. 198 pg/ml, P＜0.001）, 
and heart rate （HR） （71.0 beats/min vs. 67.0 beats/min, P＝0.021） upon discharge 
during the primary admission.  Multivariate logistic analysis identied LVEF ＜40％, 
BMI ＜21 kg/m2, BNP ≥ 500 pg/ml, Charlson score ≥ 3, and HR ≥ 70 beats/min 
upon initial discharge as independent prognostic factors.  Based on these factors, 
readmission for worsening HF was more frequent in those with our proposed risk 
score of ≥ 3.0 than in those with a risk score ＜3.0 （P＜ 0.001）, and we suggested 
ve prognostic factors for HF patients over 75 years old.  Our proposed risk score 
combines these factors and might predict readmission for worsening HF in the 
elderly population.
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Introduction
　Acute decompensated heart failure （HF） is a leading cause of admission to cardiology units, 
with the majority of patients improving immediately.  However, maintaining a clinical condi-
tion by pharmacotherapy is seldom straight forward, and patients often experience readmission 
for worsening HF 1）.  Recently, the Japanese Cardiac Registry of Heart Failure in Cardiology 
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（JCARE-CARD） study reported a 27％ readmission incidence for worsening HF within 6 
months from discharge 2）.
　HF is especially common in elderly people, with the worldwide increase in incidence with 
advancing age likened to a pandemic 3）.  Unlike younger patients, elderly patients with HF usually 
have comorbidities 4） that often render them refractory to conventional guideline-based treatment 5）.
　Recently, potentially inappropriate medications （PIMs） have attracted attention in the optimiza-
tion of pharmacotherapy for elderly patients, whose frequently decreased ability to metabolize 
medications make them more prone to therapy-related harm.  PIMs in particular have been 
associated with adverse events due to drug-disease and drug-drug interactions 6）, and patients 
with many diseases are generally treated with many prescriptions, which probably include PIMs. 
Many countries have developed strategies and criteria for identifying and screening PIMs ; 
however, while one systematic review associated PIMs with readmission 7）, a cohort study on HF 
patients using the Beers criteria found no such association 8）.  Therefore, the role of PIMs in 
readmissions of HF patients is still controversial.
　Risk scores 9-11） developed to predict mortality in HF patients are considered useful for 
decision-making on the intensity of treatment, such as device therapy or palliative care.  On 
the other hand, risk scores for predicting readmission for worsening HF are still under develop-
ment12）.  Thus, our study aimed to elucidate the relevant prognostic factors for worsening HF in 
patients over 75 years old to develop a risk score for predicting readmission.
Patients and methods
Study overview
　We collected data retrospectively from the medical records of patients ≥75 years old who 
were hospitalized for HF at Showa University Hospital from January 1, 2016 to December 31, 
2018.  We excluded any repeat hospitalization for HF during the study period.  We explored the 
prognostic factors for readmission due to worsening HF by comparing clinical indices between 
readmitted and non-readmitted patients.  We excluded the following patient groups from the data 
analysis : readmitted patients hospitalized premeditatedly or for a reason not related to worsening 
HF ; non-readmitted patients defined as outpatients of Showa University hospital ; and, those 
who were followed-up at clinic, entered a nursing facility, or received home care.  We dened 
the follow-up period as 6 months from discharge, and the last follow-up day was May 30, 2019. 
Patients who died during the primary hospitalization or were transferred to another hospital were 
also excluded.  The School of Pharmacy, Showa University ETHICAL COMMITTEE （Permit 
Number 324） approved this research, and information was disclosed with an opt-out clause.
Variables
　We collected data on variables considered potential prognostic factors for readmission due to 
worsening HF, as follows : age ; gender ; clinical scenario and New York Heart Association clas-
sication upon admission ; vital signs, weight, medications, echocardiography data, and laboratory 
data upon discharge ; status of comorbidities ; length of stay ; past HF admission ; and socioeco-
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nomic status.  Charlson scores were calculated as an index of comorbidity status 13）, based on the 
International Classication of Diseases 10th revision.  The medications upon discharge included 
only those prescribed by the physicians and excluded those that were taken on an as-needed 
basis.  PIMs upon discharge were assessed using three criteria : 1） Beers criteria 6）; 2） Screening 
Tool of Persons Prescription （STOPP）14）; and 3） Screening Tool of Persons Prescription-Japan 
（STOPP-J）15）.  Missing data were excluded from statistical analysis.
Statistical analysis
　All continuous variables were presented as mean ± standard deviation or as a median （inter-
quartile range）.  All categorical variables were presented as frequency （percentage）.  For com-
parisons of continuous variables, unpaired Student’s t-test was used for parametrically distributed 
data, and the Mann-Whitney U-test was used for non-parametrically distributed data.  Fisher’s 
exact test was used to compare categorical variables.
　We developed a risk score for predicting readmission in three steps.  First, we identified 
the candidate variables associated with readmission for worsening HF using univariate analysis. 
Variables with a P＜0.2 by univariate analysis and those that were clinically important were 
chosen as the candidate variables.  Second, we extracted the prognostic factors by stepwise 
multivariate logistic regression analysis and excluded candidate variables showing P ≥ 0.05.  Con-
tinuous candidate variables included in the regression equation were categorized as dichotomous 
variables, based on receiver operating characteristic （ROC） curves.  Considering the collinearity, 
we used variance ination factors.  The degree of association between the prognostic factors and 
readmission for worsening HF was expressed as odds ratios （OR） and 95％ condence intervals 
（CI）.  Third, we developed a risk score for predicting readmission for worsening HF, based on 
the logistic regression equation.  The weight given to each variable was based on the natural 
logarithm of the OR 16）.
　We evaluated the discrimination ability of our proposed risk score using the area under the 
ROC （AUROC） curve and 95％ CI.  Based on the risk score that gave the maximum sum of 
the sensitivity and specicity on the ROC curve, we stratied HF patients into 2 groups.  The 
incidences of readmission for worsening HF in both groups were analyzed by the Kaplan-Meier 
method and were compared using the log rank test.
　All analyses were two-tailed, and P＜0.05 was considered to be statistically signicant.  Statisti-
cal analyses were performed using EZR version 1.37 （Jichi Medical University, Saitama, Japan）17）.
Results
　Figure 1 shows the study population owchart.  Of the 340 patients discharged, 99 patients 
could not become outpatients of Showa University hospital and 75 patients were readmitted for 
reasons excluding worsening HF.  We therefore included 165 patients in our study.  During the 
study period, there were 65 （39.4％） patients readmitted for worsening HF.
　Table 1 details the patients’ baseline characteristics.  Compared with non-readmitted patients, 
those who were readmitted for worsening HF had a lower body mass index （BMI） （19.9 kg/m2 
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vs. 21.4 kg/m2）, left ventricular ejection fraction （LVEF） （39％ vs. 50％）, and higher B-type 
natriuretic peptide （BNP） levels （478 pg/ml vs. 198 pg/ml）; diastolic blood pressure （DBP） （64.0 
mmHg vs. 61.0 mmHg）; serum creatinine （1.3 mg/dl vs. 1.1 mg/dl）; and heart rate （HR） （71.0 
beats/min vs. 67.0 beats/min） upon discharge.  The Charlson score was numerically higher in 
patients readmitted for worsening HF than in the non-readmitted patients （P＝0.039）.  With 
regard to the medications upon discharge, patients who were readmitted for worsening HF 
received less prescriptions for angiotensin converting enzyme （ACE）/ angiotensin receptor 
blocker （ARB） （40％ vs. 60％, P＝0.017） and mineralocorticoid receptor antagonist （MRA） 
（31％ vs. 49％, P＝0.024）.  On the other hand, upon discharge, the number of medications and 
the number of STOPP-J PIMs were not signicantly different between the groups.
　Based on the univariate analysis, we adopted 17 candidate variables, including male gender, 
systolic blood pressure, BMI, LVEF, BNP, DBP, serum creatinine, HR, hypertension, atrial brilla-
tion, length of stay, HF hospitalization history, alone （Home environment）, Charlson score, ACE/
ARBs, MRAs, and loop diuretics.  The results of the multivariate logistic regression analysis are 
shown in Table 2.  Of the 17 candidate variables, 5 variables （Charlson score ≥ 3, LVEF ＜ 40％, 
BMI ＜ 21 kg/m2, HR ≥ 70 beats/min, and BNP ≥ 500 pg/ml） were extracted as the prognostic 
factors.  The ROC curves and the risk scores for each prognostic factor are shown in Figure 2. 
At an AUROC curve of 0.81 （95％ CI 0.75-0.88）, the sum of the sensitivity and specicity was 
maximum at a risk score of 3.0 points.  The Kaplan-Meier curves are shown in Figure 3.  Read-
missions for worsening HF were more frequent in patients with a risk score ≥ 3.0 points than in 
those with risk scores ＜ 3.0 points （log-rank, P＜ 0.001）.
Fig. 1.  Patient flowchart
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Table 1.  Baseline characteristics of the patients
Readmission for worsening HF （n＝65） No readmission （n＝100） P
Age （years）† 85.6±5.3 84.7±5.2 0.259
Male 24 （37） 51 （51） 0.081
Vital signs at discharge
　Systolic BP （mmHg） 118 （105-132） 110 （100-126） 0.056
　Diastolic BP （mmHg） 64.0 （57.0-72.0）    61.0 （54.0-68.0）  0.046＊
　Heart rate （beats/min） 71.0 （67.0-80.0）     67.0 （59.0-78.0）  0.021＊
　BMI （kg/m2） 19.9 （17.9-22.1） （n＝61） 21.4 （19.7-23.3） （n＝94）  0.007＊
NYHA classification Ⅱ  7 （11） 10 （10） Reference
 （admission）        Ⅲ 12 （18） 35 （35） 0.236
                    Ⅳ 46 （71） 55 （55） 0.797
Laboratory data at discharge
　Hemoglobin （g/dl） 11.0±1.7 11.3±1.9 0.362
　Serum creatinine （mg/dl） 1.3 （1.0-1.7） 1.1 （0.9-1.4）   0.008b＊
　BNP （pg/ml） 478 （233-689） 198 （106-313） ＜0.001＊
Echocardiography at discharge
　LVEF （％） 39 （32-53） 50 （39-58）  0.002＊
Comorbidity
　Hypertension 51 （78） 89 （89） 0.077
　Diabetes mellitus 16 （25） 20 （20） 0.564
　Ischemic heart failure 35 （54） 52 （52） 0.873
　Atrial brillation 24 （37） 51 （51） 0.081
　Charlson score 3.0 （2.0-5.0） 3.0 （1.8-4.0）  0.039＊
Length of stay （days） 19 （14-34） 19 （14-26） 0.175
HF hospitalization history 27 （42） 31 （31） 0.184
Home environment （n＝61） （n＝94）
　With son or daughter 30 （49） 56 （60） Reference
　Old couple 16 （26） 23 （24） 0.552
　Alone 15 （25） 15 （16） 0.192
Medication at discharge
　Medications （n） 9.8±3.6 9.9±3.5 0.966
　STOPP-J PIMs （n） 2.0 （1.0-3.0） 2.0 （2.0-3.0） 0.719
　STOPP PIMs （n） 1.0 （0-2.0） 2.0 （0-2.0） 0.912
　Beers PIMs （n） 0 （0-2.0） 0 （0-1.0） 0.732
　ACE inhibitors/ARBs 26 （40） 60 （60）  0.017＊
　MRAs 20 （31） 49 （49）  0.024＊
　β blockers 57 （88） 80 （80） 0.288
　Loop diuretics 58 （89） 96 （96） 0.114
　Statins 30 （46） 44 （44） 0.873
Data given as mean±SD, median （IQR） or n （％）. †Age of the patients range from 75 to 99. ACE, angiotensin convert-
ing enzyme ; ARB, angiotensin receptor blocker ; BMI, body mass index ; BNP, b-type natriuretic peptide ; BP, blood pres-
sure ; HF, heart failure ; IQR, interquartile range ; LVEF, left ventricular ejection fraction ; MRA, mineralocorticoid receptor 
antagonist ; NYHA, New York Heart Association ; PIMs, potentially inappropriate medications ; SD, standard deviation ; 
STOPP, Screening Tool of Person’s Prescription ; STOPP-J, Screening Tool of Person’s Prescription-Japan. ＊P＜0.05
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Discussion 
　Herein, we elucidated ve prognostic factors that were associated with readmission for wors-
ening HF in elderly patients.  The number of discharge medications that fullled the SOPP-
J criteria for PIMs was not extracted as a prognostic factor.  Hamaguchi et al.18） previously 
Fig. 2.   Discrimination of the considered risk score for predicting readmission for 
worsening heart failure
 The Area under the ROC curve is 0.81 （95％ CI 0.75-0.88）. The considered risk 
score ranges from 0-6 points.  At 3.0 point, the maximum sum of the sensitivity 
and specificity is 70.0％ and 81.7％, respectively. BMI, body mass index ; BNP, 
B-type natriuretic peptide; HR, heart rate; LVEF, left ventricular ejection fraction; 
ROC, receiver-operating characteristic.
Table 2.  Prognostic factors for readmission for worsening HF based on multivariate analysis
OR 95％ CI P
Charlson score ≥ 3 2.38 1.04-5.44 0.040
LVEF＜40％ 2.41 1.02-5.66 0.044
BMI＜21kg/m2 2.63 1.20-5.79 0.016
HR≥70beats/min 3.64 1.62-8.17 0.002
BNP≥500pg/ml 5.41 1.91-15.3 0.001
ACE, angiotensin converting enzyme ; ARB, angiotensin receptor blocker ; BMI, body mass index ; 
BNP, b-type natriuretic peptide ; BP, blood pressure ; CI, condence interval ; HF, heart failure ; HR, 
heart rate ; LVEF, left ventricular ejection fraction ; MRA, mineralocorticoid receptor antagonist.
P＜0.05, by stepwise logistic regression analysis.
Candidate variables : Male gender, Systolic BP ≥110 mmHg, Diastolic BP ≥70 mmHg, HR ≥70 beats/min, 
serum creatinine ≥1.2 mg/dL, BNP ≥500 pg/mL, BMI ＜21 kg/m2, LVEF ＜40％, Hypertension, Atrial 
fibrillation, Carlson score ≥3, Length of stay ≥28 days, HF hospitalization history, Alone, ACE 
inhibitors/ARBs, MRAs, Loop diuretics
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suggested that lower estimated glomerular ltration, nitrate use, and no hypertensive heart failure 
were associated with readmission for worsening HF in patients ≥ 80 years old with HF.  Our 
results thus add further evidence to validate the previous study.  To the best of our knowledge, 
our study was the rst to consider the risk score for predicting readmission for worsening HF in 
elderly patients.  Unlike the predictive formula of Sakamoto et al 19）, comprising 50 parameters, 
our proposed and simple risk score might more easily drive the readmission for worsening HF 
in ve factors.  Our proposed risk score of ≥ 3.0 points sufciently discriminated those patients 
who needed readmission for worsening HF.
　A study by Lai et al 7）. supported our results on the absence of an association between read-
mission for worsening HF and the number of discharge medications that fullled the STOPP-
J criteria.  Based on the STOPP-J criteria, the PIMs identified loop diuretics in 154 （93％） 
patients and spironolactone in 66 （40％） patients （data not shown）.  These medications have 
been frequently used for HF treatment.  However, in another setting, some of the medications 
that fullled the STOPP-J criteria and were associated with worsening HF, such as non-steroidal 
anti-inammatory drugs 20） and pioglitazone 21）, could also play in the readmission for worsening 
HF.  The Charlson score is calculated by the sum of weighted score assigned to 17 comorbidities 
separately, based on the relative risk of mortality.  This assignment included HF and chronic kid-
Fig. 3.   Incidence rates of readmission for worsening heart failure according to our proposed 
risk scores
 The Kaplan-Meier curve for the time to readmission for worsening heart failure was 
less decreased for our proposed risk score of ＜ 3.0 points than for our proposed 
risk score of ≥ 3.0 points. BMI, body mass index ; BNP, B-type natriuretic peptide ; 
HR, heart rate; LVEF, left ventricular ejection fraction
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ney disease, which means patients with both disease have Charlson score ≥ 3.  A meta-analysis 
suggested that chronic kidney disease was associated with all-cause death in HF patients 22）.  This 
study partly supported our result on the association of Charlson score ≥ 3 with readmission for 
worsening HF.  Shama et al 23）. suggested that lower BMI was associated with cardiac mortality 
in patients with HF.  Their results supported our nding that a BMI＜ 21 kg/m2 was associ-
ated with readmission for worsening HF.  The decrease of BMI may express malnutrition, and 
malnutrition is an independent prognostic factor in HF patients 24）.  A prior study based on the 
JCARE-CARD registry suggested few differences in the incidence of readmission for worsen-
ing HF between LVEF ≥ 50％ and LVEF＜ 40％ 25）.  Their results may seem to contradict our 
results.  However, this difference may be accounted for by our inclusion criterion of patients ≥
75 years old.  In the BEAUTIFUL study, subanalyses of the morbidity mortality with the 
ivabradine in patients with coronary disease and left ventricular dysfunction suggested that a 
HR ＞ 70 beats/min was associated with admission for worsening HF in patients with LVEF ＜
40％ 26）; their results was similar to ours.  van Veldhuisen et al. 27） suggested that a high BNP 
was associated with readmission for worsening HF.  Their results supported our nding that a 
BNP ≥500 pg/ml was associated readmission for worsening HF.  A recent study showed that 
BNP-targeted treatment has no effect the readmission for worsening HF in patients ≥ 75 years 
old 28）.  We may decrease the readmission for worsening HF by monitoring Charlson Score, BMI, 
LVEF, and HR in addition to BNP.  In a systematic review that included 10 studies on the use 
of risk scores to predict readmission in HF patients 12）, the range of the AUROC curves was 
0.60 to 0.82.  The discrimination of our considered risk score was relatively good, but may have 
been overtting, because it was evaluated using the derivation cohort.  To evaluate the extent of 
overtting, a validation study on another cohort is needed.
　Our study had some limitations.  First, we analyzed a relatively small sample size, mainly due 
to the exclusion criteria for readmitted and non-readmitted patients.  Excluding the discharged 
patients except outpatients of Showa University Hospital, we prevented the possibility discharged 
patients being readmitted to another hospital.  Second, our study was based on a single setting, 
and thus might not be applicable to the general population.  However, compared with prior 
studies, our study identied similar prognostic factors for HF patients.  Third, based on the retro-
spective nature of data collection from the medical records, the proper intake of the prescribed 
medications after discharge was not veried.  Further studies are needed to evaluate the associa-
tion between medication adherence and the prognosis of elderly HF patients.  
　In conclusion, in HF patients ≥ 75 years old, the Charlson score ≥ 3, LVEF ＜ 40％, BMI ＜
21 kg/m2, HR ≥ 70 beats/min, and BNP ≥ 500 pg/ml were associated with readmission for wors-
ening HF.  Therefore, the considered risk score, which comprises these prognostic factors, might 
predict the readmission for worsening HF in patients ≥ 75 years old.
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